We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Abbott Diagnostics

  Gold Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

High-Sensitivity Troponin I Explored Post-Cardiac Surgery

By LabMedica International staff writers
Posted on 07 Mar 2022
Print article
Image: The Architect STAT Troponin-I assay is a 2-step chemiluminescent microparticle immunoassay designed to detect cardiac troponin I (cTnI) in serum and plasma using the ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics)
Image: The Architect STAT Troponin-I assay is a 2-step chemiluminescent microparticle immunoassay designed to detect cardiac troponin I (cTnI) in serum and plasma using the ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics)

Consensus recommendations regarding the threshold levels of cardiac troponin elevations for the definition of perioperative myocardial infarction and clinically important periprocedural myocardial injury in patients undergoing cardiac surgery range widely.

Although cardiac surgery has the potential to improve the quality and prolong the duration of a patient’s life, it is associated with complications. Prognostically important myocardial injury, detected by an elevated concentration of either cardiac troponin or creatine kinase MB4, is one of the most common complications after cardiac surgery and is associated with increased mortality.

A large international team of clinical scientists led by those from McMaster University (Hamilton, ON, USA) recruited patients from a convenience sample of 24 hospitals in 12 countries from May 2013 through April 2019. Patients were enrolled from North America (35.9%), Asia (28.3%), Europe (26.2%), South America (6.3%), and Australia (3.3%). The mean age of the study cohort was 63.3 years, 70.9% of the patients were men, 29.3% had a history of myocardial infarction, and 70.2% were White. Blood samples were obtained for measurement of cardiac troponin I levels with the ARCHITECT STAT assay (Abbott Laboratories, Abbott Park, IL, USA), (upper reference limit, 26 ng/L; limit of detection, 1 to 2 ng/L liter) before surgery, 3 to 12 hours after surgery, and on days 1, 2, and 3 after surgery.

The team reported that within the first day after surgery, troponin was measured in 13,662 patients. Among these patients, 13,316 patients (97.5%) had a peak troponin measurement of more than 260 ng/L (>10 times the upper reference limit), 12,217 patients (89.4%) had a peak troponin measurement of at least 910/L (≥35 times the upper reference limit), and 10,205 patients (74.7%) had a peak troponin measurement of at least 1,820 ng/L (≥70 times the upper reference limit). By 30 days after surgery, 296 patients (2.1%) had died and 399 patients (2.9%) had had a major vascular complication. Among patients who underwent other cardiac surgery, the corresponding threshold troponin level was 12,981 ng/L (95% CI, 2673 to 16,591), a level 499 times the upper reference limit.

The authors concluded that the levels of high-sensitivity troponin I after cardiac surgery that were associated with an increased risk of death within 30 days were substantially higher than levels currently recommended to define clinically important periprocedural myocardial injury. The study was published on March 3, 2022 in the journal The New England Journal of Medicine.

Related Links:
McMaster University 
Abbott Laboratories 

 

Gold Supplier
SARS-CoV-2 Assay
INgezim COVID 19 SPIKE CROM
New
Dengue Real-Time RT-PCR Test
Simplexa Dengue Kit
New
Fecal Occult Blood Test
iFOB Assay
New
Nucleic Acid Extractor
SMART-05

Print article
SUGENTECH INC.

Channels

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.